AANS Online Scientific Sessions: Tumor-Exploiting Inherent DNA Damage Repair Defects in IDH1/2 Mutated Gliomas With the CNS-Penetrant PARP Inhibitor BGB290

Exploiting Inherent DNA Damage Repair Defects in IDH1/2 Mutated Gliomas With the CNS-Penetrant PARP Inhibitor BGB290

Video Transcription

Video Summary

The video presentation discusses the work entitled "Exploiting Inherent DNA Damage Repair Defects in IDH1 and 2 Mutated Gliomas with the CNS Penetrant PARP Inhibitor BGB290". It explains that patients with IDH1 and 2 mutant tumors in glioma have longer survival and respond better to chemotherapy and radiation. The presentation highlights that IDH1 and 2 mutant tumors have a homologous recombination defect, making them sensitive to PARP inhibitors. The researchers tested the therapeutic synergy of BGB290 with temozolomide and radiation in IDH1-mutated glioma cells and found preferential cell killing. Additionally, they demonstrated that BGB290 crosses the blood-brain barrier and selectively penetrates tumor tissue in an in vivo model. No credits were mentioned.

Asset Subtitle

Christopher S. Hong, MD

Keywords

DNA Damage Repair

IDH1 Mutated Gliomas

PARP Inhibitor

Therapeutic Synergy

Blood-Brain Barrier